PSEN1

Across TCGA pan-cancer cohorts, PSEN1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PSEN1 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSEN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSEN1 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where PSEN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.223	0.701	<.001	21	view →
CCRCC	OS	Median	All	0.622	1.000	.002	9	view →
GBM	OS	Quartile	All	0.557	0.275	.028	6	view →
UCEC	DFS	Median	All	0.826	0.956	.024	6	view →
LSCC	DFS	Tertile	III,IV	1.000	0.518	.049	2	view →
HNSC	DFS	Median	II,III,IV	0.981	0.913	.011	2	view →
PDAC	DFS	Tertile	All	0.715	0.883	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PSEN1–LUAD (DFS)

Open the LUAD breakdown →